RAGE 229

Key Product Details

Product Description

RAGE 229 is an antagonist of the interaction between the cytoplasmic tail of the receptor for advanced glycation end products (ctRAGE) and the formin, Diaphanous-1 (DIAPH1) (K_D for binding to ctRAGE = 2 nM). RAGE 229 inhibits the migration of human aortic smooth muscle cells in an in vitro wound healing assay (IC₅₀ = 120 nM). RAGE 229 reduces short- and long-term complications of diabetes in mouse models, without lowering blood glucose concentrations. RAGE 229 also reduces plasma concentrations of TNF-α, IL-6, and CCL2/JE-MCP1 and attenuates inflammatory signaling in diabetic mice.

Licensing Information

Sold under license from New York University

Product Specifications for RAGE 229

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for RAGE 229

The following data is based on the product molecular weight 386.45.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.59 mL	12.94 mL	25.88 mL
5 mM	0.52 mL	2.59 mL	5.18 mL
10 mM	0.26 mL	1.29 mL	2.59 mL
50 mM	0.05 mL	0.26 mL	0.52 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Manigrasso Small-molecule antagonism of the interaction of the RAGE cytoplasmic domain with DIAPH1 reduces diabetic complications in mice. Sci.Transl.Med. 2021 PMID: 34818060

Product Documents for RAGE 229